10 Best Growth Stocks Under $30 to Buy Now

In this article, we will discuss the 10 Best Growth Stocks Under $30 to Buy Now.

On June 12, Rick Rieder, BlackRock CIO, joined CNBC’s ‘Closing Bell’ to discuss the overall picture for equity markets and the tech market. Rieder emphasized that the current environment is exceptionally dynamic and fast-paced, largely due to the incredible speed at which technology is changing the world. He characterized his current investment philosophy as dynamic patience. He explained that this requires adapting to the constant flow of news, managing risk actively, and thinking through instances where the market overreacts in either direction.

He insisted that investors must maintain two core convictions: staying in equity positions, as he expects them to perform well throughout the year, and capitalizing on the current phenomenal income environment. Drawing on four decades of experience, he emphasized that the strategy of compounding income remains highly effective. However, Rieder noted that the environment becomes trickier when rates, equities, and gold all correlate, as this removes the traditional hedging dynamics that investors usually rely on. Consequently, while he suggests that investors can still lean in, they must be careful regarding potential left tail risks because they lack the protection of standard hedges.

Addressing the recent correction in technology stocks that had previously seen massive gains, Rieder offered his perspective on the market’s current state. He remarked that, in his long career, he has never seen markets driven so heavily by momentum, with investors crowding onto one side of the boat to chase daily themes until they become overexposed. When asked if the market is in a bubble, Rieder said no and noted that corporate earnings remain very strong. However, he acknowledged that the market displays some characteristics of a bubble because of the intense over-demand, followed by a scenario where everyone attempts to exit their positions simultaneously. While he believes that the market must go through a period of digestion to work through this, he maintained that investors should stick to their core positions, as the underlying fundamentals are profound enough to ensure continued success.

Our Methodology

We used screeners to identify stocks that have a track record of delivering earnings growth and have grown their EPS by at least 30% over the past 3 years. We then looked for stocks trading below $30 and limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds

Note: All data was sourced on June 15. 

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).

10 Best Growth Stocks Under $30 to Buy Now

10. Klarna Group plc (NYSE:KLAR)

Number of Hedge Fund Holders: 40

Klarna Group plc (NYSE: KLAR) is one of the best growth stocks under $30 to buy now. On June 9, Klarna launched FDIC-insured savings accounts in the US, offering users an interest rate starting at 3.28% APY. These accounts, held by WebBank, feature no monthly fees or minimum deposit requirements and are fully integrated into the existing Klarna app. This move brings a successful European model to the American market, where Klarna has already managed over $12.3 billion in consumer deposits across eleven other regions.

The new savings product allows consumers to manage their finances within a single platform, eliminating the need to switch apps. To help users grow their wealth effortlessly, the account includes automated tools such as round-ups, scheduled transfers, and custom savings goals. Klarna aims to challenge traditional banking by providing competitive rates directly where its millions of American users already manage their daily spending.

CEO Sebastian Siemiatkowski emphasized that Klarna Group plc (NYSE:KLAR) is positioning itself as a comprehensive financial hub, enabling users to manage their entire financial picture, from the Klarna Card to savings, in one place. While the service is live, customers should note that deposit insurance is provided through WebBank, and the competitive APY is subject to specific membership requirements and balance limitations.

Klarna Group plc (NYSE:KLAR) is a global fintech company offering payment and shopping solutions. It specializes in “buy now, pay later” services, enabling consumers to split payments or defer purchases while helping merchants boost sales through flexible checkout options.

9. Invivyd Inc. (NASDAQ:IVVD)

Number of Hedge Fund Holders: 42

Invivyd Inc. (NASDAQ:IVVD) is one of the best growth stocks under $30 to buy now. On June 9, Invivyd dosed the first participants in its LIBERTY Phase 3 clinical trial, a study comparing the safety and tolerability of its monoclonal antibody candidate, VYD2311, against mRNA COVID-19 vaccines. The randomized, double-blind trial involves ~210 healthy adults and includes 3 treatment arms to assess the effects of VYD2311 alone, the vaccine alone, and both administered concurrently. Invivyd expects to report topline data in Q3 2026, which will support its ongoing regulatory efforts.

This trial is a key component of Invivyd’s broader REVOLUTION clinical program, which seeks to position VYD2311 as a more tolerable, vaccine-alternative prophylactic for COVID-19. Chairman Marc Elia highlighted the urgent need for prevention options that avoid the systemic side effects associated with mRNA vaccines, noting that concerns over these reactions have contributed to declining booster uptake. The study aims to provide clinical evidence that could differentiate the safety profile of mAb-mediated prophylaxis from traditional immunization.

VYD2311 is an investigational antibody engineered for neutralization of contemporary COVID-19 lineages, using an intramuscular administration route designed for patient convenience. LIBERTY results will complement data from the company’s pivotal DECLARATION Phase 3 trial, which is currently evaluating the efficacy of VYD2311 in a broader population of ~2,400 participants. Together, these trials form the foundation for Invivyd Inc.’s (NASDAQ:IVVD) goal of establishing a new standard of care in COVID-19 prevention.

Invivyd Inc. (NASDAQ:IVVD) develops next‑generation antibody drugs aimed at long‑lasting effectiveness against evolving viruses, utilizing a proprietary platform to deliver durable therapies.

8. CytomX Therapeutics Inc. (NASDAQ:CTMX)

Number of Hedge Fund Holders: 42

CytomX Therapeutics Inc. (NASDAQ:CTMX) is one of the best growth stocks under $30 to buy now. On June 3, CytomX expanded its research collaboration with Regeneron to develop next-gen conditionally-activated bispecific cancer therapies. By combining CytomX’s PROBODY masking platform with Regeneron’s Veloci-Bi technology, the partnership aims to create treatments that remain inactive until reaching the tumor microenvironment, potentially widening the therapeutic window and minimizing off-target effects.

Under the expanded agreement, CytomX will receive a $37 million target selection payment for two new programs. Furthermore, Regeneron has secured an option for six additional targets, bringing the total potential value of the collaboration, including research, development, regulatory, and sales-based milestones, to ~$4 billion, in addition to tiered royalties on future product sales.

Regeneron will remain responsible for funding the subsequent preclinical, clinical, and commercialization activities. Both companies emphasized that this expansion builds on the success of their initial 2022 alliance, reinforcing a shared commitment to advancing precision immunotherapy for challenging tumor types.

CytomX Therapeutics Inc. (NASDAQ:CTMX) is a clinical-stage biopharmaceutical company developing “masked” antibody therapeutics, known as PROBODY platforms, designed to activate specifically within tumor microenvironments. This approach targets cancer while minimizing damage to healthy tissue, focusing on antibody-drug conjugates/ADCs and T-cell engagers to treat advanced cancers.

7. Gitlab Inc. (NASDAQ:GTLB)

Number of Hedge Fund Holders: 43

Gitlab Inc. (NASDAQ:GTLB) is one of the best growth stocks under $30 to buy now. On June 2, GitLab reported strong FQ1 2027 results, with total revenue rising 23% year-over-year to $264.2 million. The company improved its non-GAAP operating margin to 14% and generated $146.7 million in non-GAAP adjusted free cash flow. This solid financial performance reflects growing enterprise demand for GitLab’s intelligent DevSecOps platform as organizations seek trusted solutions for software orchestration in the evolving AI era.

Operationally, the company expanded its “GitLab Duo Agent Platform” and deepened integrations with Anthropic, AWS, and Google Cloud to support enterprise-scale AI security and automation. Despite this growth, GitLab announced a strategic restructuring plan to optimize its operations, which includes a 14% workforce reduction and an exit from 22 countries. The company expects these measures to incur approximately $30 million to $35 million in pre-tax charges while realigning the organization toward its core strategic priorities.

Gitlab Inc. (NASDAQ:GTLB) provided a revenue outlook of $1.112 billion to $1.118 billion for fiscal year 2027. While management maintains a focus on high-return initiatives and shareholder value, evidenced by recent share repurchases, the company is balancing these investments with the structural changes needed to ensure long-term efficiency. GitLab remains committed to its role as a unified platform for the full software lifecycle, aiming to navigate the shift toward agentic AI while maintaining its enterprise market position.

Gitlab Inc. (NASDAQ:GTLB) develops and operates a comprehensive DevSecOps platform delivered as a single application, allowing teams to plan, build, secure, and deploy software faster. The company provides an all-in-one solution that integrates source code management, continuous integration/continuous deployment (CI/CD) pipelines, and security monitoring.

6. Relmada Therapeutics Inc. (NASDAQ:RLMD)

Number of Hedge Fund Holders: 44

Relmada Therapeutics Inc. (NASDAQ:RLMD) is one of the best growth stocks under $30 to buy now. On May 12, Relmada Therapeutics reported Q1 2026 results, highlighted by positive 12-month Phase 2 data for its NDV-01 candidate, which showed a 95% complete response rate in high-risk non-muscle invasive bladder cancer. The company is well-capitalized with $234 million in cash, expected to fund operations through 2029, including the completion of its upcoming Phase 3 RESCUE registrational program scheduled to initiate in mid-2026.

Operationally, Relmada Therapeutics Inc. (NASDAQ:RLMD) is increasing its clinical profile by presenting these findings and the Phase 3 design at the upcoming American Urological Association Annual Meeting. Additionally, the company is strengthening its long-term market position through a new provisional patent application filed in April 2026, which could extend protection for NDV-01 formulations and treatment methods until 2047 if issued.

Management continues to emphasize NDV-01’s potential as a best-in-class therapy, noting its streamlined in-office administration and favorable safety profile. With its balance sheet bolstered by a recent $160 million financing, the company remains focused on executing the RESCUE program and advancing its oncology portfolio toward commercial viability.

Relmada Therapeutics Inc. (NASDAQ:RLMD) is an American clinical-stage biotechnology company based in Florida. It focuses on the development of treatments for various conditions, including bladder cancer and metabolic diseases. Its portfolio includes at least drug candidates in Phase 2 trials, and at least one in a Phase 1 stage.

Click to continue reading and see the 5 Best Growth Stocks Under $30 to Buy Now.

Disclosure: None. None. Follow Insider Monkey on Google News.